Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Gregory T, Notte"'
Autor:
Sarah A Gilmore, Danny Tam, Tara L Cheung, Chelsea Snyder, Julie Farand, Ryan Dick, Mike Matles, Joy Y Feng, Ricardo Ramirez, Li Li, Helen Yu, Yili Xu, Dwight Barnes, Gregg Czerwieniec, Katherine M Brendza, Todd C Appleby, Gabriel Birkus, Madeleine Willkom, Tetsuya Kobayashi, Eric Paoli, Marc Labelle, Thomas Boesen, Chin H Tay, William E Delaney, Gregory T Notte, Uli Schmitz, Becket Feierbach
Publikováno v:
PLoS ONE, Vol 17, Iss 12, p e0271145 (2022)
Chronic hepatitis B (CHB) is a global health care challenge and a major cause of liver disease. To find new therapeutic avenues with a potential to functionally cure chronic Hepatitis B virus (HBV) infection, we performed a focused screen of epigenet
Externí odkaz:
https://doaj.org/article/f4644c5b4458489dba69140ec4acc22c
Discovery of Potent and Selective MTH1 Inhibitors for Oncology: Enabling Rapid Target (In)Validation
Autor:
Julie Farand, Jeffrey E. Kropf, Peter Blomgren, Jianjun Xu, Aaron C. Schmitt, Zachary E. Newby, Ting Wang, Eisuke Murakami, Ona Barauskas, Jawahar Sudhamsu, Joy Y. Feng, Anita Niedziela-Majka, Brian E. Schultz, Karen Schwartz, Serge Viatchenko-Karpinski, Dmytro Kornyeyev, Adam Kashishian, Peidong Fan, Xiaowu Chen, Eric B. Lansdon, Michael O. Ports, Kevin S. Currie, William J. Watkins, Gregory T. Notte
Publikováno v:
ACS Med Chem Lett
[Image: see text] We describe the discovery of three structurally differentiated potent and selective MTH1 inhibitors and their subsequent use to investigate MTH1 as an oncology target, culminating in target (in)validation. Tetrahydronaphthyridine 5
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a8664fe5cf60201d9c5d872c2fbdf25
https://europepmc.org/articles/PMC7074220/
https://europepmc.org/articles/PMC7074220/
Autor:
David G. Breckenridge, Laurie A. Castonguay, Giuseppe A. Papalia, Swetha Pendem, Shawn S. Badal, Ford Hinojosa-Kirschenbaum, Gregory T. Notte, Sarah Wise, Michael V. Lee, Keith A. Koch, Agnes B. Fogo, Dorothy French, Britton Kenneth Corkey, Frank Y. Ma, Brian E. Schultz, Eric B. Lansdon, Melanie H. Wong, David J. Nikolic-Paterson, Tareq M Al-Tuhaifi, Theodore Sullivan, Michael Graupe, Haichun Yang, Erik Huntzicker, Grant R. Budas, John T. Liles
Publikováno v:
Journal of Clinical Investigation. 128:4485-4500
Oxidative stress is an underlying component of acute and chronic kidney disease. Apoptosis signal–regulating kinase 1 (ASK1) is a widely expressed redox-sensitive serine threonine kinase that activates p38 and c-Jun N-terminal kinase (JNK) mitogen-
Autor:
Deepa Hammaker, Grant R. Budas, Julie A. Di Paolo, Gyrid Nygaard, Gary S. Firestein, Igor Mikaelian, Gregory T. Notte, Vivian Barry, David L. Boyle
Publikováno v:
Biochemical Pharmacology. 151:282-290
Despite improved therapy, rheumatoid arthritis (RA) remains an unmet medical need. Previous efforts to validate therapeutic targets in the mitogen-activated protein kinase (MAPK) family have had minimal success. Therefore, we evaluated the potential
Autor:
Dmitry O, Koltun, Eric Q, Parkhill, Elfatih, Elzein, Tetsuya, Kobayashi, Gregory T, Notte, Rao, Kalla, Robert H, Jiang, Xiaofen, Li, Thao D, Perry, Belem, Avila, Wei-Qun, Wang, Catherine, Smith-Maxwell, Arvinder K, Dhalla, Sridharan, Rajamani, Brian, Stafford, Jennifer, Tang, Nevena, Mollova, Luiz, Belardinelli, Jeff A, Zablocki
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 26:3202-3206
We started with a medium throughput screen of heterocyclic compounds without basic amine groups to avoid hERG and β-blocker activity and identified [1,2,4]triazolo[4,3-a]pyridine as an early lead. Optimization of substituents for Late INa current in
Autor:
Jeff A, Zablocki, Elfatih, Elzein, Xiaofen, Li, Dmitry O, Koltun, Eric Q, Parkhill, Tetsuya, Kobayashi, Ruben, Martinez, Britton, Corkey, Haibo, Jiang, Thao, Perry, Rao, Kalla, Gregory T, Notte, Oliver, Saunders, Michael, Graupe, Yafan, Lu, Chandru, Venkataramani, Juan, Guerrero, Jason, Perry, Mark, Osier, Robert, Strickley, Gongxin, Liu, Wei-Qun, Wang, Lufei, Hu, Xiao-Jun, Li, Nesrine, El-Bizri, Ryoko, Hirakawa, Kris, Kahlig, Cheng, Xie, Cindy Hong, Li, Arvinder K, Dhalla, Sridharan, Rajamani, Nevena, Mollova, Daniel, Soohoo, Eve-Irene, Lepist, Bernard, Murray, Gerry, Rhodes, Luiz, Belardinelli, Manoj C, Desai
Publikováno v:
Journal of medicinal chemistry. 59(19)
Late sodium current (late I
Autor:
Gregory T. Notte
This year's chapter of New Chemical Entities Entering Phase III Trials provides an overview of novel synthetic organic molecules entering Phase III clinical trials in the United States. From the 1390, Phase III trials registered at ClinicalTrials.gov
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c9a2c72d34eb01416ddbe3d41e244b28
https://doi.org/10.1016/b978-0-12-800167-7.00026-2
https://doi.org/10.1016/b978-0-12-800167-7.00026-2
Autor:
Gregory T. Notte
This year’s chapter of New Chemical Entities Entering Phase III Trials provides an overview of novel synthetic organic molecules entering Phase III clinical trials in the United States. From the 1426 Phase III trials registered at ClinicalTrials.go
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2fb64170e8fc505e2db6fa04f7d0088f
https://doi.org/10.1016/b978-0-12-417150-3.00027-2
https://doi.org/10.1016/b978-0-12-417150-3.00027-2
Autor:
Gregory T. Notte
This year's inaugural chapter of New Chemical Entities Entering Phase III Trials provides an overview of novel synthetic organic molecules entering Phase III clinical trials. From the 1537 Phase III trials registered at ClinicalTrials.gov in 2011 cla
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eb120e087faa44b8d47916a2c8925fe4
https://doi.org/10.1016/b978-0-12-396492-2.00030-8
https://doi.org/10.1016/b978-0-12-396492-2.00030-8
Publikováno v:
ChemInform. 42
The reactions allow efficient asymmetric access to α-aryl-β-hydrazido esters and α,α-disubstituted β-hydrazido nitriles.